FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4231665822> ?p ?o ?g. }

• W4231665822 endingPage "603" @default.
• W4231665822 startingPage "597" @default.
• W4231665822 abstract "BACKGROUND A Phase II trial was conducted to determine the response rate of patients with advanced renal cell carcinoma to a three-drug combination of 5-fluorouracil (5-FU), interleukin-2 (IL-2), and interferon-α-2b (IFN-α). METHODS A 2-stage accrual plan was used that was designed to determine whether response to this regimen was consistent with a true response rate of ≥ 30%. The regimen was comprised of 5 treatment days weekly for 4 weeks every 6 weeks. Each weekly treatment was comprised of 5-FU, 1750 mg/m2, continuous intravenous (i.v.) infusion over 24 hours followed by IL-2, 6 MIU/m2/day, continuous i.v. infusion for 4 days. IFN-α, 6 MU/m2, was given subcutaneously on Days 1, 2, and 5. RESULTS Thirty-eight patients were entered on study, 3 of whom were ineligible. Among the 35 eligible patients there were 3 confirmed partial responses (PR) and 1 complete response (CR), for an overall response rate of 11% (95% confidence interval, 3–27%). One patient considered as having a PR had minimal evidence of residual disease and was free from disease progression at > 2.5 years of follow-up, as was the patient with CR. Three additional patients not qualified as having a PR were showing signs of response at the time they were removed from protocol, and another patient who was removed from protocol early for management of an infection subsequently responded to the same regimen off protocol. Thirteen patients were considered nonassessable (NASS) for response, many of whom had multiple poor risk features and were unable to complete 1 cycle of treatment. CONCLUSIONS This multicenter study failed to confirm an advantageous overall response rate for this three-drug regimen. However, there were two durable responses and indications of responsiveness not scored as PRs among patients with more favorable risk factor patterns, and many poor risk NASS patients. For these reasons, the response rate reported in the current study may be a conservative reflection of the effectiveness of this regimen. Cancer 2000;89:597–603. © 2000 American Cancer Society." @default.
• W4231665822 created "2022-05-12" @default.
• W4231665822 creator A5008068115 @default.
• W4231665822 creator A5009958231 @default.
• W4231665822 creator A5021616410 @default.
• W4231665822 creator A5029895694 @default.
• W4231665822 creator A5034852534 @default.
• W4231665822 creator A5050649350 @default.
• W4231665822 creator A5058286630 @default.
• W4231665822 creator A5068040261 @default.
• W4231665822 creator A5077337021 @default.
• W4231665822 creator A5090579073 @default.
• W4231665822 date "2000-08-01" @default.
• W4231665822 modified "2023-10-01" @default.
• W4231665822 title "Infusional interleukin‐2 and 5‐fluorouracil with subcutaneous interferon‐α for the treatment of patients with advanced renal cell carcinoma" @default.
• W4231665822 doi "https://doi.org/10.1002/1097-0142(20000801)89:3<597::aid-cncr15>3.3.co;2-5" @default.
• W4231665822 hasPublicationYear "2000" @default.
• W4231665822 type Work @default.
• W4231665822 citedByCount "0" @default.
• W4231665822 crossrefType "journal-article" @default.
• W4231665822 hasAuthorship W4231665822A5008068115 @default.
• W4231665822 hasAuthorship W4231665822A5009958231 @default.
• W4231665822 hasAuthorship W4231665822A5021616410 @default.
• W4231665822 hasAuthorship W4231665822A5029895694 @default.
• W4231665822 hasAuthorship W4231665822A5034852534 @default.
• W4231665822 hasAuthorship W4231665822A5050649350 @default.
• W4231665822 hasAuthorship W4231665822A5058286630 @default.
• W4231665822 hasAuthorship W4231665822A5068040261 @default.
• W4231665822 hasAuthorship W4231665822A5077337021 @default.
• W4231665822 hasAuthorship W4231665822A5090579073 @default.
• W4231665822 hasBestOaLocation W42316658221 @default.
• W4231665822 hasConcept C126322002 @default.
• W4231665822 hasConcept C126894567 @default.
• W4231665822 hasConcept C141071460 @default.
• W4231665822 hasConcept C2776694085 @default.
• W4231665822 hasConcept C2777472916 @default.
• W4231665822 hasConcept C2780456651 @default.
• W4231665822 hasConcept C2781413609 @default.
• W4231665822 hasConcept C44249647 @default.
• W4231665822 hasConcept C71924100 @default.
• W4231665822 hasConcept C90924648 @default.
• W4231665822 hasConceptScore W4231665822C126322002 @default.
• W4231665822 hasConceptScore W4231665822C126894567 @default.
• W4231665822 hasConceptScore W4231665822C141071460 @default.
• W4231665822 hasConceptScore W4231665822C2776694085 @default.
• W4231665822 hasConceptScore W4231665822C2777472916 @default.
• W4231665822 hasConceptScore W4231665822C2780456651 @default.
• W4231665822 hasConceptScore W4231665822C2781413609 @default.
• W4231665822 hasConceptScore W4231665822C44249647 @default.
• W4231665822 hasConceptScore W4231665822C71924100 @default.
• W4231665822 hasConceptScore W4231665822C90924648 @default.
• W4231665822 hasIssue "3" @default.
• W4231665822 hasLocation W42316658221 @default.
• W4231665822 hasOpenAccess W4231665822 @default.
• W4231665822 hasPrimaryLocation W42316658221 @default.
• W4231665822 hasRelatedWork W1922523666 @default.
• W4231665822 hasRelatedWork W2003612179 @default.
• W4231665822 hasRelatedWork W2016770806 @default.
• W4231665822 hasRelatedWork W2086004237 @default.
• W4231665822 hasRelatedWork W2334004086 @default.
• W4231665822 hasRelatedWork W2363409655 @default.
• W4231665822 hasRelatedWork W2369685086 @default.
• W4231665822 hasRelatedWork W2418637712 @default.
• W4231665822 hasRelatedWork W2418999078 @default.
• W4231665822 hasRelatedWork W933517682 @default.
• W4231665822 hasVolume "89" @default.
• W4231665822 isParatext "false" @default.
• W4231665822 isRetracted "false" @default.
• W4231665822 workType "article" @default.